ClinicalTrials.gg
TerminatedNCT04165551Updated Oct 8, 2026

Evaluation of the Consumption of a Probiotic on the Load of S. Agalactiae.

A Phase 1 interventional study of Probiotic and Placebo in Streptococcus Agalactiae, sponsored by Biosearch S.A.. Terminated at 1 site in Spain. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Biosearch S.A. (part of Kerry Group plc) · Phase 1, Interventional, and Prevention

Why this study was terminated
The study was terminated due to low enrollment
Updated Oct 8, 2026Now TerminatedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The objective of this study is to evaluate the effects of oral administration of Lactobacillus BSL_PS71 on the presence of S. agalactiae in vaginal microbiota of healthy women.

Read the detailed description

Group B streptococci (Streptococcus agalactiae) are found in the vaginal microbiota in 10-30% of women without showing signs of infection. However, during delivery, it can be transmitted to the baby and, although in most cases it does not lead to disease, in a percentage of 5% of babies it causes serious infections that can trigger the death of the baby. In order to avoid this risk, a protocol of intra-partum preventive administration of antibiotics was implanted decades ago in women with a positive vaginal culture for this species in the weeks before birth. Taking into account the high percentage of women who show positive culture, this represents a high percentage of women who receive preventive antibiotic treatment with the consequences that this has for the mother's and baby's microbiota, as well as contributing to the generation of antibiotic resistance, a serious problem for today's society.

The fecal microbiota is considered a source of bacteria for the vaginal microbiota. In fact, women who present S. agalactiae in the vaginal microbiota also have it in stool. Given the demonstrated ability of Lactobacillus to control certain bacterial populations, the ability of a battery of Lactobacillus strains to inhibit the growth of S. agalactiae in the context of the fecal microbiota was analyzed. From these tests the strain Lactobacillus BSL_PS71 was selected for its antibacterial capacity against S. agalactiae.

02

Conditions studied

  • Streptococcus Agalactiae

Keywords

  • Streptococcus agalactiae
  • ProbioticsPrevention
03

In context

Lead sponsor

Biosearch S.A. is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Biosearch S.A. became part of Kerry Group plc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Test positive for S. agalactiae in vaginal exudate
  • Accept freely to participate in the study and sign the document

Exclusion criteria

Exclusion Criteria:

  • Consumption of probiotic supplements
  • Antibiotic use in the period of 2 weeks before the start of the study
  • Being pregnant or intending to get pregnant in the next 8 weeks
  • Being allergic to any group of antibiotics
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Probiotic

    Volunteers will take 1 capsule per day containing 6x109 cfu of Lactobacillus BSL\_PS71 in maltodextrin.

    Biological: Probiotic

  • Placebo comparator
    Placebo

    Volunteers will take 1 capsule per day containing maltodextrin.

    Biological: Placebo

Interventions

  • BiologicalProbiotic

    Volunteers will take 1 capsule a day of the Probiotic during lunch without any restrictions on diet or lifestyle.

  • BiologicalPlacebo

    Volunteers will take 1 capsule a day of the Placebo during lunch without any restrictions on diet or lifestyle.

06

What researchers measure

Primary outcomes

  1. Detection of Streptococus agalactiae in vaginal exudate

    It will be determined the presence of S. agalactiae in vaginal exudate

    Time frame: 8 weeks

Secondary outcomes

  1. Cuantification of bacterial populations in vaginal exudate

    It will be cuantified the bacterial populations in vaginal exudate

    Time frame: 8 weeks

07

Study locations

1 site
  • Biosearch Life
    Granada, Andalusia 18004, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Sep 2020, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Nov 18, 2019
StartActual
Oct 1, 2019
Primary completionActual
Sep 1, 2020
CompletionActual
Sep 10, 2020
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated The study was terminated due to low enrollment
changed Oct 8, 2026
Sites
1 site added, 1 site removed
Show site
  • Biosearch Life · Granada, Spain
Show 1 removed
  • Biosearch Life · Granada, Spain
Oct 8, 2026
Enrollment
60 (estimated)→3 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Status unknown→Terminated
    Why stopped The study was terminated due to low enrollment
    1 site added, 1 site removed
    Show site
    • Biosearch Life · Granada, Spain
    Show 1 removed
    • Biosearch Life · Granada, Spain
    Enrollment 60 (estimated)→3 (actual)
    + 5 other changes: index terms, date precision, description, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04165551
Lead sponsor
Biosearch S.A.
Collaborators
Federico García García, PhD
Responsible party
Sponsor
First posted
Nov 18, 2019
Start date
Oct 1, 2019
Primary completion
Sep 1, 2020
Completion
Sep 10, 2020
Last update
Oct 8, 2026

Study contacts

Federico García, PhD
study chair · Head of the Microbiology Service at the San Cecilio Hospital (Granada, Spain)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion